Sensorion receives €950,000 from Bpifrance and the Occitania Region

Bpifrance and the Occitania region of Southern France have selected to support Sensorion, a biotechnology company specializing in the treatment of inner ear diseases, via a €950,000 interest-free innovation loan after a competitive selection process.

The purpose of this funding is to strengthen the Sensorion preclinical platform by implementing High Content Screening (HCS) approaches, focused on discovering new drugs for inner-ear disorders.

The HCS approach will add higher throughput phenotypic capacity for screening new molecules, and will enable further detailed studies of their properties and impact on new therapeutic targets in the inner ear, Sensorion said in its press release issued on Thursday.

Sensorion’s platform has already generated 3 orally active drug candidates targeting inner-ear disorders.

Laurent Nguyen, CEO of Sensorion said that this latest funding will enable the company to continue increasing its technological lead by developing an even more efficient screening platform for selecting relevant molecules and therapeutic targets to treat patients suffering from vertigo, hearing loss or tinnitus.



Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.